TL;DR - Mass tort settlement amounts vary widely depending on injury severity, diagnosis type, length of exposure, and the strength of medical evidence. - Individual per-case amounts in major settled MDLs have ranged from roughly $100,000 to over $550,000, with outliers well above and below those figures. - A settlement matrix assigns point values to each plaintiff's injuries and documentation, producing an individual compensation figure from the overall fund. - Before any payment reaches a plaintiff, attorney fees (33-40%), common benefit assessments (4-8%), and medical liens are deducted. - Cases in MDLs without a global settlement yet, such as the J&J talcum powder litigation, have no fixed payment ranges until bellwether trials establish value.
Mass tort settlement amounts are one of the first things injured people want to understand. The honest answer is that there is no universal figure. A plaintiff with a documented cancer diagnosis and 20 years of product exposure will receive a very different amount than someone with a less severe injury and limited exposure records.
What is predictable are the factors that drive compensation up or down, the process by which individual amounts are calculated from a larger settlement fund, and what real MDLs have actually paid in recent settlements. This guide covers all three.
What determines mass tort settlement amounts?
Five factors drive individual compensation in most mass tort settlements: injury severity, diagnosis type, length of exposure, strength of medical documentation, and the outcomes of bellwether trials that preceded the global deal.
Injury severity is typically the single largest variable. A plaintiff who developed a terminal cancer receives a substantially higher settlement offer than one who experienced reversible symptoms. Most settlement structures rank injuries explicitly, from least severe to most severe, and assign corresponding compensation tiers.
Diagnosis type matters because some injuries have stronger scientific causation links to the defendant's product than others. In the Camp Lejeune litigation, for example, kidney cancer, bladder cancer, and non-Hodgkin's lymphoma receive priority processing because the epidemiological evidence connecting those conditions to water contamination is strongest.
Length and intensity of exposure affects both eligibility and compensation. Most MDLs require a minimum documented exposure period. Plaintiffs who can show longer or more intensive exposure generally receive higher offers.
Medical documentation quality is often the deciding factor between two plaintiffs with similar diagnoses. A claim supported by detailed medical records, pathology reports, and expert physician review scores higher on the settlement matrix than one relying on incomplete records.
Bellwether trial outcomes set the ceiling and floor for negotiations. Consistent plaintiff wins push defendants toward higher per-case offers across the board; defense wins have the opposite effect. A full explanation of how bellwether verdicts feed into settlement value is available on this site.
How do settlement matrices work?
A settlement matrix is a structured scoring formula that converts each plaintiff's individual facts into a specific compensation figure from the overall settlement fund.
The matrix assigns point values to documented injury severity, diagnosis type, exposure duration, and the quality of medical evidence. A claims administrator, typically a neutral third party appointed as part of the settlement agreement, reviews each plaintiff's submitted documentation and scores it against the matrix. The score determines which compensation tier applies and what the individual payment will be.
Disputes over scores can be escalated to arbitration within the settlement process. This keeps individual disagreements from reopening the broader global deal. The full claims administration process moves through documentation review, matrix scoring, dispute resolution, and final distribution, often over a period of months to years after the global settlement is reached.
Recent mass tort settlement amounts: what real MDLs have paid
Published figures from resolved and partially resolved MDLs give the clearest picture of real-world mass tort settlement amounts.
Roundup (Bayer/Monsanto)
The Roundup litigation is the most thoroughly documented large-scale MDL settlement in recent history. Bayer committed more than $11 billion to resolve approximately 100,000 claims. Phase 1 individual settlements were reported in the range of $100,000 to $160,000 per case. Phase 2 values were anticipated to be higher, reflecting the escalating pattern of bellwether verdicts.
The three bellwether trials that preceded the settlement produced jury awards of $289 million, $80 million, and $2 billion, all substantially reduced on appeal but consistently favoring plaintiffs. Those results gave both sides the information needed to negotiate.
Camp Lejeune
The Camp Lejeune water contamination litigation uses an Elective Option track with published tier ranges. Individual settlements span approximately $100,000 to over $550,000 per claim, depending on the qualifying condition and the strength of exposure documentation. The Department of Justice had disbursed more than $700 million in Camp Lejeune settlements as of March 2026, with 649 new settlements approved in that month alone totaling $175 million.
The Congressional Budget Office estimated total Camp Lejeune liability at approximately $21 billion, though final outcomes depend on how many qualifying claims are ultimately resolved.
AFFF Firefighting Foam (PFAS)
The AFFF litigation has produced large settlements for water utility plaintiffs but not yet for individual personal injury claimants. 3M agreed to pay $10.3 billion over 13 years to resolve contamination claims from public water systems. DuPont and related entities committed $1.185 billion for similar claims.
The approximately 8,000 individual personal injury cases in the MDL remain active as of early 2026, with per-case values dependent on bellwether trial outcomes not yet concluded.
Johnson and Johnson Talcum Powder
The talcum powder litigation has no global settlement in place as of the date of this article. J&J's $9 billion bankruptcy settlement attempt was rejected by a federal judge on March 31, 2025. Individual trial verdicts have ranged from nine to ten figures, including a $1.56 billion award in a February 2026 Baltimore trial, but those figures apply only to the individual plaintiffs in those cases. With the MDL now proceeding toward federal bellwether trials, settlement values remain unestablished for the broader plaintiff group.
What gets deducted before you receive payment?
Three categories of deductions reduce the amount a plaintiff actually receives from a mass tort settlement: attorney fees, common benefit assessments, and medical liens.
Attorney contingency fees in mass tort cases typically run 33 to 40 percent of the individual recovery. This fee covers the plaintiff's own attorney for case preparation and representation. No fee is owed if the case produces no recovery.
Common benefit fees of approximately 4 to 8 percent may apply on top of the contingency. These fees compensate lead counsel, the attorneys who managed shared pre-trial work such as coordinated discovery and expert witness preparation, for efforts that benefited all plaintiffs in the MDL. Common benefit fees are typically deducted from the settlement fund before individual distributions rather than added separately.
Medical liens must be resolved before a plaintiff receives their net payment. Medicare, Medicaid, and private insurers who paid for treatment related to the plaintiff's injury have a legal right to reimbursement from any settlement recovery. Lien resolution is handled during claims administration and can meaningfully reduce the final amount a plaintiff takes home.
A plaintiff who receives a gross settlement offer of $150,000 might net $75,000 to $90,000 after accounting for all three categories. The specific deductions depend on the fee agreements in place and the size of any medical liens.
Why two plaintiffs with the same diagnosis can receive different amounts
Two plaintiffs diagnosed with the same cancer from the same product can receive substantially different settlement offers, and the reasons are predictable.
Exposure documentation is a common differentiator. A plaintiff who can produce purchase records, medical records connecting the diagnosis to the product, and an expert physician report supporting causation will score higher on the settlement matrix than a plaintiff with the same diagnosis but limited documentation.
Pre-existing conditions that overlap with the alleged injury can also reduce compensation. A claims administrator reviewing a non-Hodgkin's lymphoma claim in a case where the plaintiff had prior exposure to other known risk factors may assign a lower score than for a plaintiff with no confounding history.
Case-specific evidence matters too. The glossary on this site defines many of the terms that appear in claims administration paperwork, including Daubert standards for expert evidence and the difference between general and specific causation, both of which affect how individual claims are scored.
When does settlement money get paid?
Settlement payments reach plaintiffs after the claims administration process is complete, which typically takes months to years after a global deal is announced.
The sequence follows a fixed order: the global settlement is reached and a fund is established; plaintiffs submit documentation to the claims administrator; each claim is reviewed and scored against the settlement matrix; disputed scores go through arbitration; approved claims receive payment offers; plaintiffs accept or reject; and approved distributions are paid, sometimes as lump sums and sometimes in installments.
For large MDLs with tens of thousands of claimants, this process can extend over several years. The nine-stage MDL process described on this site places claims administration at Stage 8 and fund distribution at Stage 9, both occurring after the settlement negotiation at Stage 7.
What this means if your case has no settlement yet
If the MDL your case is part of has not reached a global settlement, there are no established per-case ranges to reference. Settlement values in those cases will be shaped by bellwether trial results still to come.
This is the current situation for talcum powder plaintiffs and AFFF personal injury claimants, among others. It does not mean compensation is unavailable. It means the negotiation process that produces a published range has not concluded. Following bellwether trial outcomes in your MDL is one of the most practical ways to track how the litigation is progressing toward resolution.
The individual case pages on this site track current litigation status, settlement developments, and bellwether trial schedules for all active cases covered on this site.
The information on mass-torts.com is for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by using this website. Laws vary by state and jurisdiction. For advice about your specific situation, consult a licensed attorney in your jurisdiction. mass-torts.com is not a law firm and does not provide legal representation.